SPRAVATO® is the first FDA-approved nasal spray for adults with treatment-resistant depression and major depressive disorder. Esketamine is administered in a certified treatment center under the supervision of a certified healthcare provider.
Treatment-resistant depression (TRD) is a term most commonly used in clinical psychiatry to describe cases of depressive disorders, such as Major Depressive Disorder and Bipolar Disorders, that do not respond adequately to at least two antidepressants. In the last 20 years, research has consistently shown that low doses of ketamine can rapidly relieve depressive symptoms in patients whose depression has been otherwise resistant to treatment.
Ketamine therapy is very effective on the following types of depression:
- Treatment Resistant Depression (MDD)
- Bipolar Depression (BPD)
- Depression from Traumatic Brain Injury (TBI)
- Anxiety Disorders
- Sleep-Wake Disorders
- Substance Use Disorder
SPRAVATO® is a ketamine-based prescription nasal spray that is taken along with an oral antidepressant. It increases glutamate, a naturally occurring chemical in the brain that helps transmit messages between brain cells. When glutamate increases, communication between brain cells improves, positively affecting mood.
Studies show those who took Esketamie Nasal Spray experienced more significant reductions in depression symptoms at four weeks compared to those who received a placebo plus an oral antidepressant. SPRAVATO® works quickly and has a high success rate, giving new hope to those who have not found relief from their current depression prescription and treatment plans.
SPRAVATO® (nasal esketamine) is chemically similar to ketamine and is offered in a nasal spray version as an in-office treatment. It is FDA-approved and covered by insurance, and a savings plan is available for the co-payments. You can also contact SPRAVATO withMe to enroll by calling 844-479-4846.
Because SPRAVATO® is a psychedelic treatment medication, it must be taken as an outpatient in a certified facility. Behavioral Health Resiliency PLLC is an accredited Risk Evaluation and Mitigation Strategy (REMS) program specially trained to monitor the use of SPRAVATO®. Under the instruction of the health care provider, you will administer the nasal spray to yourself.
Wondering what to expect? See more here. You remain in the office for about 2 hours. You will be monitored and cared for, including monitoring you for any side effects.
Treatments are provided twice weekly for four weeks, weekly for four weeks, then weekly/every other week before a tapering course (at least four months of treatment); treatments last a minimum of two hours.
We delight in the beauty of the butterfly, and rarely admit the changes it has gone through tp acheive the beauty ~ Maya Angelou